Company Filing History:
1 out of 3,540 
1 out of 1 Years Active: 2006-2015
Title: Magnus Essand - Innovator in Immunotherapy
Introduction
Magnus Essand is an accomplished inventor based in Vänge, Sweden. He is currently associated with Elicera Therapeutics AB, where he focuses on groundbreaking research in immunotherapy. Despite having no granted patents to his name, his contributions to the field are noteworthy.
Latest Patent Applications
Magnus Essand has been involved in several significant patent applications. One of his latest applications is for "Anti-IL13R-alpha2 Antibodies, Antigen-Binding Fragments and Uses Thereof." This invention relates to antibodies and antigen-binding fragments capable of binding to IL13Rα2. These antibodies are particularly useful in constructing chimeric antigen receptors (CARs) and in CAR-based immunotherapy for treating IL13Rα2-expressing cancer diseases. Another application is titled "T-CELL IMMUNOTHERAPY." This application describes T-cells useful in T-cell immunotherapy that comprise a CAR, TCR, and/or nucleic acid sequences encoding a CAR and/or a TCR. The T-cells also include HP-NAP and have improved effects in immunotherapy, including enhanced cytotoxicity and stimulation of chemokine and cytokine secretion.
Conclusion
Magnus Essand is a dedicated inventor making strides in the field of immunotherapy through his innovative research and patent applications. His work holds promise for advancing cancer treatment methodologies.